drugset
drugset / Trial / NCT05985200

A Study in Healthy People to Test How Well Repeated Doses of BI 3032950 Are Tolerated

NCT05985200 ↗

Phase 1 Completed 40 enrolled Boehringer Ingelheim
RandomizedParallel-groupSingle-blindTreatment

Summary

The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics and pharmacodynamics following multiple rising intravenous doses of BI 3032950 in healthy male subjects and postmenopausal or surgically sterilised female subjects (women not of child bearing potential (WNOCBP)).

Timeline

Start
2023-09-15
Primary completion
2024-08-19
Completion
2024-08-19

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 3032950 Unknown — Intravenous

Indications

No indication recorded.